Verition Fund Management
ATRS

Verition Fund Management’s Antares Pharma, Inc. ATRS Stock Holding History

Verition Fund Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-58,754
Closed -$167K – 1383
2017
Q1 		$167K Buy
+58,754
New +$141K 0.02% 1065
2014
Q3 		– Sell
-14,197
Closed -$38K – 912
2014
Q2 		$38K Buy
+14,197
New +$42.7K ﹤0.01% 643

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verition Fund Management's ATRS Position: Q2 2017 in Review

Verition Fund Management sold out of Antares Pharma, Inc. (ATRS) in Q2 2017, closing a stake of 58,754 shares — an estimated $167K sold.

Verition Fund Management first reported a position in ATRS in Q2 2014 and held it in 2 quarters. The position peaked at $167K in Q1 2017. 103 funds tracked by Wall St. Rank hold ATRS as of Q2 2017.

  • Verition Fund Management reported no remaining Antares Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
  • Verition Fund Management sold 58,754 Antares Pharma, Inc. shares in Q2 2017, an estimated $167K.
  • Verition Fund Management first reported a position in Antares Pharma, Inc. in Q2 2014 and held it in 2 quarters.
  • Verition Fund Management's Antares Pharma, Inc. position peaked at $167K in Q1 2017.
  • 103 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2017.

Based on Verition Fund Management's 13F filing for Q2 2017, filed 15 Aug 2017.